Patents Examined by Marianne DiBrino
  • Patent number: 12115214
    Abstract: The invention relates a compound comprising (a) a peptide and (b) a carrier, wherein said peptide having at least the motif X-X-X-X-X-X-X, wherein at least one amino acid residue X is glycosylated, said peptide being linked to the peptide binding protein and said carrier comprises at least a MHC binding motif being linked to said peptide as well as pharmaceutical compositions comprising said compound and the use of said compound or pharmaceutical composition for the treatment of a disease, such as an inflammatory joint disease. The subject matter of the application is exemplified with peptides derived from type II collagen such as peptides having at least the sequence AGFKGEA, or IAGFKGEQPKG, or the peptide AAAKAAA. Preferably a hydroxylysine in the peptides are glycosylated.
    Type: Grant
    Filed: November 15, 2019
    Date of Patent: October 15, 2024
    Assignee: Fraunhofer-Gesellschaft zur Forderung der angewandten Forschung e.V.
    Inventors: Rikard Holmdahl, Jan Kihlberg, Balik Dzhambazov, Mikael Vestberg
  • Patent number: 12084478
    Abstract: Fusion peptide inhibitors of human coronavirus 229E are provided. The fusion peptide inhibitors of HCOV-229E include peptide #121 (SEQ?ID?NO:?2:?HVLGDISGINASVVQIQKEIDRLNEVAKNLHESL IYLQE),?and?peptide? #125?(SEQ?ID?NO:?3:?HRLRQIRGIRARVVQIQKEIWRLNEVAKL LNESLIYLQE). The fusion peptide inhibitors of HCoV-229E may be administered to a subject in need thereof to inhibit or prevent HCOV-229E cellular entry or infection with HCoV-229E. The fusion peptide inhibitors of HCoV-229E may also be used in HCoV-229E inhibition assays.
    Type: Grant
    Filed: September 25, 2023
    Date of Patent: September 10, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventor: Mahmoud Kandeel
  • Patent number: 12053512
    Abstract: The invention provides a method of validating the therapeutic composition that is prepared for immunotherapy of a tumor or cancer. The method includes, triggering of an immune response to a neoepitope of a subject's tumor by: a) obtaining neoepitope sequence data from the tumor of a subject; b) obtaining immune competent cells; c) using the neoepitope sequence data to generate a neoepitope presentation system; d) triggering an immune response by contacting the immune competent cells with the neoepitope presentation system; and e) quantifying the triggering of the immune response from the contacted immune competent cells.
    Type: Grant
    Filed: December 5, 2017
    Date of Patent: August 6, 2024
    Assignees: NantBio, Inc., Nant Holdings IP, LLC, NantOmics, LLC
    Inventors: Kayvan Niazi, Nicholas J. Witchey, Stephen Charles Benz, Shahrooz Rabizadeh
  • Patent number: 12044680
    Abstract: The methods and kits disclosed in the present disclosure allow quantified exchange of peptides into MHC proteins. These methods and kits allow MHC proteins with exchanged peptides to be used in further applications such as cell staining. The methods and kits may also be used to quantify peptides present in complex mixtures.
    Type: Grant
    Filed: May 12, 2017
    Date of Patent: July 23, 2024
    Assignee: MBL International Corp.
    Inventor: Marc Delcommenne
  • Patent number: 12011480
    Abstract: This disclosure provides compositions and methods for promoting the formation, expansion and recruitment of TR1 cells and/or B cells in an antigen-specific manner and treating diseases and disorders in a subject in need thereof.
    Type: Grant
    Filed: May 6, 2016
    Date of Patent: June 18, 2024
    Assignee: UTI LIMITED PARTNERSHIP
    Inventor: Pedro Santamaria
  • Patent number: 11992504
    Abstract: A recombinant natural killer (NK) cell or T-cell composition is transfected with a nucleic acid encoding i) a homing receptor; ii) an antigen binding protein (ABP) or a chimeric antigen receptor (CAR) that specifically binds a target antigen; iii) an Fc Receptor; and/or iv) a secreted immune modulator selected from a TGF? inhibitor and/or IL-12, where the recombinant cell is gamma (?)-irradiated conferring inhibition of cell proliferation with transient activity of the transfected molecules including the secreted immune modulators for up to 72 hours.
    Type: Grant
    Filed: November 20, 2020
    Date of Patent: May 28, 2024
    Assignee: ImmunityBio, Inc.
    Inventors: John H. Lee, Laurent H. Boissel, Hans G. Klingemann
  • Patent number: 11987606
    Abstract: The disclosure features compounds comprising an antigen portion, a soluble Major Histocompatibility Complex (MHC) molecule portion (e.g., all or an antigen-binding portion of a soluble MHC class I molecule), and a dynamic anchor portion (e.g., an agent, such as Annexin V, that binds to phosphatidylserine). The featured compounds are useful for a variety of therapeutic applications, including, e.g., enhancing a T cell response to an antigen of interest or enhancing a T cell-driven immune response by a subject to an antigen of interest (e.g., a cancer antigen or a microbial antigen).
    Type: Grant
    Filed: March 4, 2016
    Date of Patent: May 21, 2024
    Assignee: The Johns Hopkins University
    Inventors: Tzyy-Choou Wu, Chih-Ping Mao, Chien-Fu Hung
  • Patent number: 11988669
    Abstract: The present invention relates to a method for the absolute quantification of naturally processed HLA-restricted cancer peptides, i.e. the determination of the copy number of peptide(s) as presented per cell. The present invention can not only be used for the development of antibody therapies or peptide vaccines, but is also highly valuable for a molecularly defined immuno-monitoring, and useful in the processes of identifying of new peptide antigens for immunotherapeutic strategies, such as respective vaccines, antibody-based therapies or adoptive T-cell transfer approaches in cancer, infectious and/or autoimmune diseases.
    Type: Grant
    Filed: November 15, 2019
    Date of Patent: May 21, 2024
    Assignee: Immatics Biotechnologies GmbH
    Inventors: Toni Weinschenk, Julia Leibold
  • Patent number: 11957729
    Abstract: The present invention relates to peptides, nucleic acids, and cells for use in the immunotherapy of cancer. The present invention furthermore relates to survivin-derived tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention specifically relates to three novel peptide sequences and variants thereof derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
    Type: Grant
    Filed: July 12, 2019
    Date of Patent: April 16, 2024
    Assignee: Immatics Biotechnologies GmbH
    Inventors: Hans Georg Rammensee, Stefan Stevanovic, Cecile Gouttefangeas, Toni Weinschenk, Peter Lewandrowski
  • Patent number: 11952431
    Abstract: Disclosed are peptides that specifically bind to neutrophils and uses thereof for neutrophil-targeted delivery of drugs or diagnostic agents in medical conditions including cancer as well as infectious, inflammatory and autoimmune diseases or disorders.
    Type: Grant
    Filed: December 27, 2022
    Date of Patent: April 9, 2024
    Assignees: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD., HADASIT MEIDCAL RESEARCH SERVICES & DEVELOPMENT LTD.
    Inventors: Zvika Granot, Zvi Gregorio Fridlender, Sandra Vols
  • Patent number: 11939354
    Abstract: Fusion peptide inhibitors of human coronavirus 229E are provided. The fusion peptide inhibitors of HCoV-229E include peptide #121 (SEQ ID NO: 2: HVLGDISGINASVVQIQKEIDRLNEVAKNLHESLIYLQE), and peptide #125 (SEQ ID NO: 3: HRLRQIRGIRARVVQIQKEIWRLNEVAKLLNESLIYLQE). The fusion peptide inhibitors of HCoV-229E may be administered to a subject in need thereof to inhibit or prevent HCoV-229E cellular entry or infection with HCoV-229E. The fusion peptide inhibitors of HCoV-229E may also be used in HCoV-229E inhibition assays.
    Type: Grant
    Filed: September 25, 2023
    Date of Patent: March 26, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventor: Mahmoud Kandeel
  • Patent number: 11939595
    Abstract: This disclosure provides nano-scale Artificial Antigen Presenting Cells (aAPC), which deliver stimulatory signals to lymphocytes, including T-helper lymphocytes, for use as a powerful tool for immunotherapy.
    Type: Grant
    Filed: August 23, 2019
    Date of Patent: March 26, 2024
    Assignee: The Johns Hopkins University
    Inventors: Jonathan Schneck, Mathias Oelke, Karlo Perica
  • Patent number: 11904053
    Abstract: The present technology relates generally to dry powder formulations of antibodies specific for thymic stromal lymphopoietin (TSLP), as well as methods of treating asthma, using the dry powder formulations, suitably via pulmonary delivery.
    Type: Grant
    Filed: October 27, 2020
    Date of Patent: February 20, 2024
    Assignee: MEDIMMUNE LIMITED
    Inventors: Catherine Eugenie Chaillan Huntington, Susan Hoe, Prakash Manikwar, Roland Wilhelm Kolbeck, Emma Suzanne Cohen, David Lechuga-Ballesteros, Kellisa Beth Hansen, Dexter Joseph D'Sa, Saba Ghazvini
  • Patent number: 11866461
    Abstract: Fusion peptide inhibitors of human coronavirus 229E are provided. The fusion peptide inhibitors of HCoV-229E include peptide #121 (SEQ ID NO: 2: HVLGDISGINASVVQIQKEIDRLNEVAKNLHESLIYLQE), and peptide #125 (SEQ ID NO: 3: HRLRQIRGIRARVVQIQKEIWRLNEVAKLLNESLIYLQE). The fusion peptide inhibitors of HCoV-229E may be administered to a subject in need thereof to inhibit or prevent HCoV-229E cellular entry or infection with HCoV-229E. The fusion peptide inhibitors of HCoV-229E may also be used in HCoV-229E inhibition assays.
    Type: Grant
    Filed: May 16, 2023
    Date of Patent: January 9, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventor: Mahmoud Kandeel
  • Patent number: 11859176
    Abstract: A method for in vitro activation and/or expansion of immune cells is provided, including the steps of: a) providing magnetic particles having multi-protrusive surface modified with at least one type of immuno-inducing substance, in which each magnetic particle includes a copolymer core, a polymer layer, a magnetic substance layer, and a silicon-based layer from the inside to the outside; b) providing a cell solution including at least one type of immune cell in the cell solution; and c) bringing the magnetic particles in contact with the cell solution, in which the at least one type of immuno-inducing substance on the surface of the magnetic particle activates and/or expands the at least one type of immune cell in the cell solution.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: January 2, 2024
    Assignees: Industrial Technology Research Institute, National Taiwan University Hospital
    Inventors: Cheng-Tai Chen, Chien-An Chen, Wen-Ting Chiang, Su-Feng Chiu, Pei-Shin Jiang, Jih-Luh Tang, Chien-Ting Lin, Xuan-Hui Lin
  • Patent number: 11833220
    Abstract: Provided are an artificial multi-antigen fusion protein and a preparation method thereof. The fusion protein can effectively stimulate CD8+T and CD4+ T cell immunities, and can be applied to immunodiagnostics or serve as a prophylactic or therapeutic vaccine.
    Type: Grant
    Filed: December 15, 2015
    Date of Patent: December 5, 2023
    Assignees: Oxford Vacmedix UK Ltd.
    Inventors: Shisong Jiang, Xiaobing Xia, Hanghai Ding
  • Patent number: 11819516
    Abstract: Provided herein is technology relating to immunotherapy and particularly, but not exclusively, to compositions, methods, and kits for immunotherapy and activation of T cells using a peptide-major histocompatibility complex (pMHC) assembled on a protein scaffold for patterned signal presentation of T cell activating ligands to T cells.
    Type: Grant
    Filed: November 4, 2016
    Date of Patent: November 21, 2023
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Fei Wen, Mason Smith
  • Patent number: 11813318
    Abstract: The invention provides isolated primate cells preferably human cells that comprise a genetically engineered disruption in a beta-2 microglobulin (B2M) gene, which results in deficiency in MHC class I expression and function. Also provided are the method of using the cells for transplantation and treating a disease condition.
    Type: Grant
    Filed: July 10, 2019
    Date of Patent: November 14, 2023
    Assignee: UNIVERSITY OF WASHINGTON
    Inventors: David W. Russell, Roli K. Hirata
  • Patent number: 11807675
    Abstract: The present invention relates to, in part, artificial antigen presenting cells that are useful in treating disease (including cancers) and have uses, for example, directly in vivo and/or in the expansion of a patients cells for re-introduction ex vivo.
    Type: Grant
    Filed: October 3, 2014
    Date of Patent: November 7, 2023
    Assignee: The University of Maryland, Baltimore
    Inventors: Tonya Webb, Carolyn Morris, James East
  • Patent number: 11787849
    Abstract: The invention describes kit of parts of polypeptides comprising: a) a peptide comprising: a1) an MHC class II T cell epitope or a CD1 d-restricted NKT cell epitope, and a2) immediately adjacent to said epitope or separated by at most 7 amino acids from said epitope a [CST]-X(2)-C [SEQ ID NO:7] or C-X(2)-[CST] [SEQ ID NO:8] oxidoreductase motif sequence, and b) a polypeptide comprising: b1) a therapeutic protein and b2) the epitope defined in a1), wherein the epitope sequence is a sequence which differs from the sequence of the protein of b1). The therapeutic protein, in combination with the peptide, is used to prevent an immune response against the therapeutic protein.
    Type: Grant
    Filed: September 23, 2016
    Date of Patent: October 17, 2023
    Assignee: IMCYSE SA
    Inventors: Jean-Marie Saint-Remy, Luc Vander Elst, Vincent Carlier